Development of anti-HBs titre equal to or greater than 10 mIU/ ml and of anti-D and anti-T equal to or greater than 0.01 IU/ ml measured 1-2 months after the third injection correlates with protection against hepatitis B infection and against diphtheria and tetanus respectively.